Back to Search Start Over

The use of intravenous labetalol in the setting of rapid atrial fibrillation secondary to methamphetamine use.

Authors :
Leang, Yit
Greene, Shaun L.
Koutsogiannis, Zeff
Wong, Anselm
Source :
Toxicology Communications. Dec2019, Vol. 3 Issue 1, p91-93. 3p.
Publication Year :
2019

Abstract

The use of beta-adrenoceptor antagonists for treatment of tachydysrhythmias secondary to sympathomimetic agents is controversial due to concerns of "unopposed alpha receptor stimulation." Labetalol is a dual alpha 1 and beta1/beta 2 adrenoceptor antagonist. We report the case of a 33-year-old male who developed rapid atrial fibrillation with a ventricular rate of 151 beats per minute in the setting of methamphetamine use. He received intravenous labetalol 10 mg on five occasions over a 6.5 h period, which slowed his ventricular rate and eventually resulted in restoration of sinus rhythm. Administration of labetolol did not produce a clinically significant rise in blood pressure. Combination alpha and beta blockade using labetalol may be an effective and safe treatment option in patients with methamphetamine associated supraventricular tachydysrhythmias. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
*LABETALOL
*ATRIAL fibrillation

Details

Language :
English
ISSN :
24734306
Volume :
3
Issue :
1
Database :
Academic Search Index
Journal :
Toxicology Communications
Publication Type :
Academic Journal
Accession number :
141751682
Full Text :
https://doi.org/10.1080/24734306.2019.1691325